# FDA 483 - David M. Scarpino, M.D. - January 16, 2026

Source: https://www.keypedia.com/records/483/david-m-scarpino-md/8c3e7551-62e4-488e-9523-54c650f16be4

> FDA 483 for David M. Scarpino, M.D. on January 16, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: David M. Scarpino, M.D.
- Inspection Date: 2026-01-16
- Product Type: drugs
- Office Name: Los Angeles District Office
- Summary: The FDA inspected David M. Scarpino, M.D., a clinical investigator, and identified significant deviations from the investigational plan and good clinical practices. Observations included failures to ensure subject eligibility, maintain accurate and complete case histories, and properly manage investigational drug disposition. These findings raise concerns about data integrity and adherence to study protocols.

## Related Officers

- [Samson O. Oluseye](https://www.keypedia.com/people/samson-o-oluseye/bfe102f5-25cb-4ed9-9e69-2ec5ec0a047f)

Company: https://www.keypedia.com/companies/david-m-scarpino-md/3819faa7-42c3-4ab3-8c7f-2258ec3f9bcb

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b